JUN and neoplasm: Supportively, increasing studies indicated that PRDX1 overexpression promotes tumor growth, chemoresistance and poor prognosis in cancer patients via induction of vascular endothelial growth factor (VEGF) expression 26, activation of c-Jun and transcription factor AP-1 27 or inhibition of cell apoptosis 28.